Bruise

Human medicines European public assessment report (EPAR): Cerdelga, eliglustat, Date of authorisation: 19/01/2015, Revision: 17, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Spleen, Patient, Liver, Medical Subject Headings, Marketing, Disease, INN, Metabolism, Fatigue, Heartburn, Fracture, ATC, Gaucher's disease, Capsule, International, Enzyme replacement therapy, Bone pain, Language, Mouth, CYP2D6, European Medicines Agency, Indigestion, EMS, Select, Instant messaging, Bruise, Safety, Anatomy, Anemia, IIA, Medical device

Human medicines European public assessment report (EPAR): Cerdelga, eliglustat, Date of authorisation: 19/01/2015, Revision: 17, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Cerdelga, eliglustat, Date of authorisation: 19/01/2015, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 2, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Chills, Medical Subject Headings, Diarrhea, Marketing, Immunodeficiency, Pregnancy, Agency, INN, Risk, Immune system, Fever, Fatigue, Lymph, Sanofi–GSK COVID-19 vaccine, Allergy, ATC, Messenger, Antibody, EMA, Pain, International, Vaccine, Headache, Disease, Ageing, Language, Vaccination, Swelling, Pfizer–BioNTech COVID-19 vaccine, Hypersensitivity, Oxford–AstraZeneca COVID-19 vaccine, COVID-19, European Medicines Agency, SARS-CoV-2, Select, Patient, Bruise, Safety, Anatomy, IIA

Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): VidPrevtyn Beta, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 10/11/2022, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Meningococcal disease, Protein, Acetylcholine receptor, Autoantibody, INN, GMG, Immune system, Fatigue, Risk, ATC, Antibody, Pain, International, Disease, Nose, Language, Muscle weakness, Vaccination, Neisseria meningitidis, European Medicines Agency, C5, Select, Bruise, Safety, Time, Anatomy, Contract management, Disorder, IIA, Medical device

Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, INN, B-cell lymphoma, Infection, ATC, Pharyngitis, Pneumonia, Pain, CD20, Hypertension, Capsule, International, Bleeding, European, Platelet, Disease, Nose, Neutropenia, Language, Mouth, Cancer, Chronic lymphocytic leukemia, Waldenström macroglobulinemia, Thrombocytopenia, Lymphocytosis, Death, Rituximab, CLL, Neutrophil, DSM-IV codes, European Medicines Agency, BTK, Growth, Select, Patient, Bruise, Time, Anatomy, Bone marrow, IIA, Macroglobulinemia, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Tetra, Medical Subject Headings, Marketing, Protein, INN, Immune system, Risk, Fatigue, World, H3N2, Allergy, ATC, Pain, WHO, International, Vaccine, Headache, Disease, Ageing, Language, Influenza, Tenderness, Irritability, Influenza B virus, H1N1, European Medicines Agency, World Health Organization, Select, Patient, Bruise, Safety, Anatomy, IIA, Skin

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Hereditary angioedema, INN, IIA, ATC, Pain, Blood, International, Injection, Angioedema, Ageing, Bradykinin, Language, Swelling, Abdomen, Red, European Medicines Agency, Face, Select, Caregiver, Bruise, Anatomy, HAE, Skin, Erythema, Medical device

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Marketing, Immunodeficiency, INN, Risk, Sensation, Messenger, Delta, Nausea, RMP, Vaccination, Heart, Inflammation, Back pain, SARS, Hardness, Bruise, Anatomy, IIA, Odynophagia, Hypoesthesia, Skin, Chills, Diarrhea, Fever, Fatigue, ATC, Pain, Ageing, Pregnancy, Somnolence, Arthralgia, Medical Subject Headings, Agency, Immune system, Allergy, Antibody, EMA, International, Language, Pfizer–BioNTech COVID-19 vaccine, Dizziness, Select, Patient, Vomiting, Erythema, Pericarditis, Lymph, System, Vaccine, Weakness, Headache, Abdominal pain, Swelling, Hypersensitivity, Temperature, COVID-19, SARS-CoV-2, Myalgia, Paresthesia, Rash

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Liver, Marketing, PV, INN, Hypertension, Graft-versus-host disease, Polycythemia, Hydroxycarbamide, Infection, Transplant, Splenomegaly, Bruise, Polycythemia vera, Bacteria, Anatomy, IIA, Spleen, Fever, Hypercholesterolemia, Primary myelofibrosis, ATC, Bleeding, Disease, Ageing, JAK, Neutrophil, Blood, System, Disorder, Weight gain, Enzyme, Safety, Anemia, Sepsis, Medical Subject Headings, Agency, B cell, International, Bone pain, Neutropenia, Language, Mouth, Dizziness, Thrombocytopenia, Pancreatic serous cystadenoma, Hypertriglyceridemia, Tablet, Select, Patient, Medicine, Phlebotomy, Hormone, Woman, Weight loss, Headache, Cytomegalovirus, European Medicines Agency, Growth, Janus kinase, Urinary tract infection, Medical device

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

The Ehlers-Danlos Society Receives $6.7 Million from the Mike and Sofia Segal Foundation to Advance Cutting-Edge Research for Ehlers-Danlos Syndrome

Retrieved on: 
Wednesday, December 20, 2023
Leukemia, Ehlers-Danlos Society, Quality of life, Partnership, Chronic myelomonocytic leukemia, Rupture, Research, Bone marrow, Pain, Blood, Tissue, CMML, Cardiovascular disease, EDS, Society, Subluxation, Ehlers–Danlos syndromes, Joint, Dislocation, HSD, Bruise, Diagnosis, Injury, Child

NEW YORK, Dec. 20, 2023 /PRNewswire/ -- The Ehlers-Danlos Society, the global non-profit dedicated to advancing and accelerating research in the Ehlers-Danlos syndromes (EDS) and hypermobility spectrum disorders (HSD), today announced it has received a $6.7 million funding commitment from the Mike and Sofia Segal Foundation (the "Foundation") to advance its groundbreaking research initiatives.

Key Points: 
  • The support from the Mike and Sofia Segal Foundation is invaluable in propelling our research towards earlier diagnosis.
  • In 1978, Mike and Sofia Segal arrived in the U.S. from present-day Ukraine with $120, a young child, and just two suitcases.
  • The partnership between the Ehlers-Danlos Society and the Foundation marks a significant leap forward in the quest for breakthroughs in EDS and HSD research.
  • The Ehlers-Danlos Society and the Foundation hope this investment will serve as a catalyst, inspiring related contributions and collaborations within the scientific community and beyond.

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer

Retrieved on: 
Thursday, December 14, 2023
Children, FDA, Health, General Health, Pharmaceutical, Oncology, Research, Family, Consumer, Science, Parenting, Neuroblastoma, Tenderness, Urine, Pneumonia, Huber loss, Somatic symptom disorder, Patient, Otitis media, Diagnosis, Tiffany Aching, Bruise, Liver, Chills, Hospital, Hearing loss, Vomiting, Food, Chair, American Cancer Society, EFS, Nose, Mortality, Multimedia, Division, Hematology, Pennsylvania State University, Blood, Diarrhea, Kool-Aid, Bleeding, Nausea, Development, Skin infection, Shivering, Urinary tract infection, Cough, Consortium, Risk, Sinusitis, Humble, Texas, Pain, Skin, Eflornithine, Hope, Upper respiratory tract infection, Disease, Abdomen, Tablet, Pediatric Hematology and Oncology, Sneeze, MD, Death, Immunotherapy, Pharmaceutical industry, Medical device, Nursing, Birth control, Phosphorus, Fever, USWM

High-risk neuroblastoma is a challenging disease, with a high mortality rate driven primarily by the risk of relapse after achieving remission.

Key Points: 
  • High-risk neuroblastoma is a challenging disease, with a high mortality rate driven primarily by the risk of relapse after achieving remission.
  • US WorldMeds partnered with the Beat Childhood Cancer Research Consortium at Penn State University, which conducted the preclinical and clinical research to help advance this vital therapy.
  • The Consortium represents a group of over 50 hospitals that offer collaboration through a network of childhood cancer clinical trials.
  • “We are thankful for the dedication of our partners, specifically the Beat Childhood Cancer Research Consortium, who work tirelessly to improve treatment outcomes for pediatric cancer patients.